XML 47 R37.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Revenue - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Feb. 28, 2019 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021
Disaggregation Of Revenue [Line Items] |  |  |  |  |
Revenue from collaboration agreement |  | $ 47,830,000 | $ 39,467,000 | $ 130,110,000 | $ 116,414,000
Medicare Reimbursements |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |
Revenue from collaboration agreement |  | 1,100,000 | 1,500,000 | 3,700,000 | 5,400,000
M R D Development Agreements | Maximum |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |
Additional milestone payment receivable |  | 370,500,000 |  | 370,500,000 |
Genentech Collaboration Agreement |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |
Revenue from collaboration agreement |  | 20,400,000 | $ 15,000,000.0 | 46,500,000 | $ 47,800,000
Non-refundable upfront payments received | $ 300,000,000.0 |  |  | $ 300,000,000.0 |
Genentech Collaboration Agreement | Maximum |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |
Revenue recognition expected period |  |  |  | 8 years |
Genentech Collaboration Agreement | Maximum | Regulatory Milestones |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |
Expected revenue through milestone payments |  | 75,000,000.0 |  | $ 75,000,000.0 |
Genentech Collaboration Agreement | Maximum | Development Milestones |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |
Expected revenue through milestone payments |  | 300,000,000.0 |  | 300,000,000.0 |
Genentech Collaboration Agreement | Maximum | Commercial Milestones |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |
Expected revenue through milestone payments |  | 1,430,000,000.0 |  | 1,430,000,000.0 |
Genentech Collaboration Agreement | Minimum |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |
Expected revenue through milestone payments |  | $ 1,800,000,000 |  | $ 1,800,000,000 |
Revenue recognition expected period |  |  |  | 7 years |

X
- Definition Additional milestone payment. + References No definition available. + Details
Name: | adpt_AdditionalMilestonePayment
Namespace Prefix: | adpt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Non-refundable upfront payments received. + References No definition available. + Details
Name: | adpt_NonRefundableUpfrontPaymentsReceived
Namespace Prefix: | adpt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue recognition expected period. + References No definition available. + Details
Name: | adpt_RevenueRecognitionExpectedPeriod
Namespace Prefix: | adpt_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue recognition milestone method expected milestone receivable. + References No definition available. + Details
Name: | adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
Namespace Prefix: | adpt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adpt_MedicareReimbursementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=adpt_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=adpt_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=adpt_CommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |